ClinicalTrials.gg
RecruitingNCT07159607APPEARUpdated Sep 8, 2025

Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)

An observational study in IDH-mutant Glioma (Oligodendroglioma, Astrocytoma), sponsored by LMU Klinikum. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by LMU Klinikum · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Background: The radiological follow-up of diffuse gliomas is challenged by the difficult distinction of true progression from treatment-related changes. To this end, the Response Assessment in Neuro-Oncology (RANO) Working Group has issued specific recommendation for the standardized evaluation of magnetic resonance imaging (MRI). In addition, positron emission tomography (PET) using radiolabeled amino acids allows for the delineation of metabolically active tumor regions in brain tumors, and guidelines for PET-based response assessment have been recently proposed (PET RANO 1.0). However, well-annotated data on longitudinal PET alterations before and during treatment and follow-up are missing in isocitrate dehydrogenase (IDH)-mutant gliomas, particularly as tumor entities defined by IDH mutations have been established only recently and data on PET imaging mainly rely on previous brain tumor classification frameworks.

Aims: This bicentric, prospective, observational study aims to collect data on imaging-based disease monitoring in patients with IDH-mutant gliomas. Specifically, this study aims to investigate longitudinal changes of amino acid PET tracer uptake during treatment in IDH-mutant gliomas and to evaluate the correlation between amino acid PET uptake at baseline and response to postoperative standard of care treatment.

Patient cohort/methods: Adult (age ≥ 18 years) patients diagnosed and/or treated at the Medical University of Vienna (Vienna, Austria) or the LMU Hospital Munich (Munich, Germany) with histologically verified diffuse IDH-mutant glioma (oligodendroglioma, astrocytoma of all grades) and PET imaging for routine follow-up before, during and after treatment will be included. Clinical and imaging data will be collected in a standardized manner and correlated with treatment response. Primary endpoint is progression-free survival (PFS) according to RANO 2.0 criteria, secondary endpoints include PFS according to PET-RANO 1.0 criteria, time to next intervention (TTNI) and overall survival (OS).

Originality/relevance: This study will generate data that will inform future response assessment frameworks and the design of future clinical trials in IDH-mutant glioma.

02

Conditions studied

  • IDH-mutant Glioma (Oligodendroglioma, Astrocytoma)

Keywords

  • APPEAR
  • PET-basierte Beurteilung des Therapieansprechens in Isocitrat-Dehydrogenase (IDH)-mutierten Gliomen - eine prospektive Beobachtungsstudie
  • Isocitrate dehydrogenase mutant gliomas
  • Positron emission tomography
  • FET PET
  • PET RANO
  • Amino acid PET
  • glioma
03

In context

Oligodendroglioma

414 studies on the registry are indexed under Oligodendroglioma; 33 are open to participants now.

This study's planned enrollment of 100 is close to the median of 110 across 39 observational studies indexed under Oligodendroglioma.

Browse Oligodendroglioma studies →

Lead sponsor

LMU Klinikum is the lead sponsor of 53 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult (age ≥ 18 years) patients diagnosed and/or treated at the Medical University of Vienna (Vienna, Austria) or the LMU Hospital Munich (Munich, Germany) with histologically verified diffuse IDH-mutant glioma (oligodendroglioma, CNS WHO grades 2 and 3; astrocytoma, CNS WHO grades 2, 3 and 4) and PET imaging for routinely performed response assessment before, during and after first-line treatment will be included after obtaining informed consent. In total, we expect the inclusion of 100 patients over an accrual period of 3 years.

Eligibility criteria

Inclusion Criteria:

  • ≥ 18 years
  • verified diffuse IDH-mutant glioma (astrocytoma, oligodendroglioma) of any grade as defined in the WHO classification of tumors of the central nervous system
  • Postoperative treatment according to current standard of care at the time of study inclusion
  • Performance of amino acid PET as part of clinical routine

Exclusion Criteria:

  • Inclusion in another clinical trial/ study involving an experimental therapy or study medication
  • Inclusion criteria not met
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Progression-free survival

    PET image information at baseline and follow-up as well as responses according to PET RANO 1.0 criteria will be correlated with progression-free survival (PFS) according to RANO 2.0 criteria.

    Time frame: From enrollment at least 24 months, maximal until end of study (max. 24 months after enrolment of last patient).

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — IPD may be considered upon reasonable request, depending on ethics approval

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2030, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Sep 8, 2025
StartActual
Jul 17, 2025
Primary completionEst.
Jul 16, 2030
CompletionEst.
Jul 16, 2030
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07159607
Lead sponsor
LMU Klinikum
Collaborators
Servier Affaires Médicales, Servier Deutschland GmbH
Responsible party
Nathalie Albert (Prof. Dr. med., LMU Klinikum) — Principal investigator
First posted
Sep 8, 2025
Start date
Jul 17, 2025
Primary completion
Jul 16, 2030 (estimated)
Completion
Jul 16, 2030 (estimated)
Last update
Sep 8, 2025

Study contacts

Nathalie L Albert, Prof. Dr. med
Contact
Nathalie.Albert@med-uni-muenchen.de
+4989440074646
Matthias Preusser, Prof. Dr. med.
Contact
matthias.preusser@meduniwien.ac.at
+43-1-40400-44450
Nathalie L Albert, Prof. Dr. med.
principal investigator · LMU Klinikum München

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion